Shares of Liquidia Corporation (LQDA) lost nearly 31% on Monday after the FDA delayed granting full approval to its Yutrepia (treprostinil) inhalation powder in a pair of lung disorder indications. The FDA granted tentative approval to Yutrepia for a second indication — in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug was initially granted tentative approval for use in adults with pulmonary arterial hypertension (PAH) in 2021. A tentative approval indicates ...